RN341|CAS |DC Chemicals

Cas No.:	3091508-57-2
Chemical Name:	RN341
Formula:	C₃₀H₃₄N₈Os
M.Wt:	554.71
Purity:	98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC79310	RN341	RN341 is a specific type II kinase inhibitor of LRRK2 (IC50: 296 nM). RN341 inhibits LRRK2 phosphorylation and avoids S935 dephosphorylation by stabilizing the open conformation. RN341 rescues LRRK2-mediated kinesin motility block by preventing microtubule binding. RN341 effectively inhibits LRRK2 wild-type and G2019S mutant at the cellular level. RN341 provides a new direction for Parkinson's disease research.
DC78463	RN277	RN277 is an inhibitor for LRRK2 type II kinase. RN277 can be used as a cellular tool targeting the LRRK2 inactive state. RN277 can inhibit LRRK1 kinase activity in vitro. RN277 inhibits LRRK2 kinase activity in vitro (IC50 = 70 nM). RN277 reduces phosphorylation of Rab8a dose-dependently. RN277 can be studied in research for Parkingson’s disease.
DC73146	MK-1468	MK-1468 is a potent, selective, brain-penetrant LRRK2 inhibitor with IC50 of 0.4 nM (G2019S LRRK2), potently inhibits the phosphorylation of LRRK2 serine 935 (pSer935) in hPBMCs with IC50 of 2.8 nM.
DC73145	FX2149	FX2149 (FX 2149) is a potent, BBB permeable inhibitor of LRRK2 GTP binding activity with IC90 of 10 nM, reduces PD-linked mutant LRRK2 variants (G2019S and R1441C) that bound with GTP.
DC48117	EB-42486	EB-42486 is a novel, potent, and highly selective G2019S-LRRK2 inhibitor (IC50 < 0.2 nM).
DC10360	MLi-2	MLi-2 is an a potent, highly selective, orally available, brain penetrant inhibitor of LRRK2 with an IC50 of 0.76 nM.